FILING ANALYSIS · MONDAY, NOVEMBER 2
Krystal Biotech, Inc. KRYS — 8-K: Results of Operations and Financial Condition
positive
Krystal Biotech reported strong Q3 financial results with $127.3 million in VYJUVEK global revenue and a $400 million share repurchase program, demonstrating confidence in its long-term growth prospects. The company also announced positive clinical updates for KB113 in treating basal cell carcinoma in patients with Gorlin syndrome, with over 80% of assessed lesions showing regression.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →